Pembrolizumab approved for a slew of cancers all at once

Pembrolizumab (a drug that inhibits PD-L1) recently received FDA approval for any type of cancer that’s failed to respond to first line therapy, as long as the tumor carries a specific molecular defect. Let me repeat that – ANY TYPE OF CANCER. Mind not blown yet? OK, OK – I should give you some background […]